Objective : The purpose of this study is to investigate the results of treatment using stent-angioplasty for symptomatic middle cerebral arterial (MCA) stenosis and comparison of in-stent restenosis between drug-eluting stents (DES), bare metal coronary stents (BMS) and self-expanding stents (SES).
INTRODUCTION
Intracranial atherosclerotic stenosis is responsible for approximately 5% to 10% of all strokes in mixed patient populations, and in the Asian population, this is even the most commonly found vascular lesion. 10) Endovascular therapy using primary angioplasty or stenting has been used in treatment of medically refractory patients with high-grade intracranial atherosclerotic stenoses. 5)22) However, endovascular management of intracranial stenosis is associated with a significant number of potential complications, including acute in-stent thrombosis, thromboembolism, vessel dissection, and even rupture. To date, according to some reports, these complications during angioplasty have varied widely, ranging from 0% to more than 30%. 6)7)12)13) Therefore, current treatment decisions are usually based on results of case series for each center.
Prior to introduction of self-expanding stents (SES) for intracranial stent-angioplasty, the only available stents for intracranial stenotic disease were coronary balloon mounted (balloon-expandable) stents. Since that time, many studies of intracranial stent-angioplasty have proceeded in earnest.
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The main trunk of the middle cerebral artery (MCA)
represents one of the most common sites of symptomatic intracranial atherosclerosis. 4) However, stent-angioplasty for MCA lesions remains challenging because of vascular tortuosity, small vessel diameter, and concern for perforator injury. In addition, MCA lesions are known to be highly prone to restenosis after stent-angioplasty. 32) The authors assessed the treatment results, periprocedural complications, and angiographic results of stent-angioplasty for symptomatic MCA stenosis, and then attempted to compare the results of restenosis between drug-eluting stents (DES), bare metal coronary stents (BMS), and SES. 
MATERIALS AND METHODS

Patient characteristics and Stent selection
Pre-and post-operative medications and Endovascular techniques
All patients undergoing stent-angioplasty were given dual antiplatelet therapy for at least three days be- There were no cases of repeated infarction during the FU periods; however, mild TIAs occurred in three patients within one year after stent-angioplasty (7.2 ± 5.5 months). All of these patients' symptoms were mild but identical to preoperative ones, and proved to be related to severe in-stent restenosis over 70% on FU angiography. We attempted to retreat these patients with a drug-eluting balloon (DEB) in two of three patients, and with another stent in the other patient, because the stenotic lesion was located beside the center of the previously implanted stent. All of these patients have been in a symptom-free state for at least seven months after retreatment (40 and 14 months after retreatment with DEB, seven months with another stent, respectively).
Angiographic findings
The mean percent stenosis before the procedure was 79.0 ± 8.2%, and the reference diameter (vessel diameter just distal to lesion) was 2.5 ± 0.2 mm, and the length of the lesion was 6.7 ± 2.4 mm. Table 5 . Comparisons of patients treated with coronary drug-eluting stents vs. coronary bare metal stents and self-expanding stents.
major stroke and death rates ranged from 0% to 50%
with a median of 7.7%. 13) Meanwhile, Zhang et al. 37) reported feasible results of stent-angioplasty for MCA stenosis. Although the size of the study was relatively smaller than that of the previous reports, in comparison, the author's result appears to show an equivalent or slightly better clinical outcome.
As for the restenosis, in the Stenting of Symptomatic
Atherosclerotic Lesions in the Vertebral or Intracranial
Arteries (SSYLVIA) Study, the rate of successful stent placement was 95%, however, restenosis rate of ≥ 50% at six months was 32.4%. 31) Recently, the incidence of in-stent restenosis and retreatment of this condition were intensively investigated from data of the US Wingspan Registry, and the rate of restenosis was reported as 29.8%, and an additional 4.5% of stent thromboses occurred during an average follow up period of 5.9 months. 19) The rate of recurrent stroke in the subgroup with in-stent restenosis was 6.8% and the rate of TIA was 13.8%. 19) In this study, overall restenosis over 50% was 16.1% (five of 31 cases) and giographic follow up period of 13.4 months.
However, due to the diverse composition of the kinds of stents, these figures should not be taken at face value. All cases of restenosis were bare metal stent, including coronary BMS and SES, and in case of SES (Wingspan stent), restenosis rate was 23.1%. This result is not much better than that of previous reports.
However, on the contrary, restenosis did not occur in cases with DES, although the number of cases was very small (Fig. 2) . DES has been known to be effective for reducing the risk of in-stent restenosis due to its controlled local release of antiproliferative agents, as compared with BMS in coronary stenting.
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Off-label use of drug-eluting coronary stents for treatment of intracranial atherosclerotic lesions has recently been reported. Further studies should be required in order to clarify the association between in-stent restenosis and relevant risk factors, including technical aspects mentioned above, and other medical history.
In cases of restenosis, we attempted to administer retreatment only in symptomatic patients (three of five cases). In one case, retreatment was administered using another Wingspan system, because the stenotic lesion was located beside the center of the previously implanted stent. We treated the other two patients with the DEB (Fig. 3) . All of these patients have been in a symptom-free state for at least seven months since retreatment (40 and 14 months after retreatment with a drug-eluting balloon, seven months with another stent, respectively). Several reported options, such as balloon angioplasty, another stent-angioplasty, etc, can be adopted for retreatment of restenosis.
Currently, balloon angioplasty has been adopted in the majority of cases. 12) Recently, the combination of mechanical balloon dilatation and local drug application was confirmed to be very efficient for treatment of coronary in-stent restenosis, and Vajda et al. 34) reported successful treatment results of a DEB for the patients with in-stent restenosis after stent-angioplasty for intracranial stenotic diseases. In addition, they introduced another combination of DEB followed by the SES, instead of a current bare balloon with a bare stent, such as a Gateway balloon and Wingspan stent. 35) Although conduct of further studies is needed, the DEB appears to be a promising alternative option for in-stent restenosis.
CONCLUSIONS
In this study, stent-angioplasty appeared to be safe and effective for MCA stenotic disease, however, a limitation of the current study was that the number of patients included was relatively small. It should prompt further studies on a larger scale.
The rate of in-stent restenosis was 16.1% as a whole, however, DES showed better results for prevention of restenosis, compared with BMS or SES. In this study, although the postoperative residual stenosis was one of the most noticeable differences between coronary balloon-expandable stents and SES, it appears to have little direct relationship with in-stent restenosis.
